India, Nov. 11 -- SpyGlass Pharma, Inc. (SGP), a late-stage biopharmaceutical company focused on chronic eye conditions, reported wider third-quarter losses
The company reported a net loss of $24.3 million, or $0.73 per share, compared with a net loss of $9.8 million, or $4.53 per share, in the year-ago quarter.
Research and development expenses increased to $10 million from $8.1 million, primarily reflecting higher clinical personnel costs and continued enrollment in Phase 3 trials. General and administrative expenses rose to $16.2 million from $3 million, mainly due to higher professional fees and personnel costs.
For comments and feedback contact: editorial@rttnews.com
Published by HT Digital Content Services with permission from RTT...